Phase 2 N=11 Development of Ivermectin for Alcohol Use Disorders
Alcohol Use Disorder
Primary: Heart Rate — 64.57; 68.36; 66.82; 62.82 BPM — p=0.0563
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=400 A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
Breast Cancer
Primary: Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Neoadjuvant Treatment Period — 1.5; 0…
Phase 2 N=13 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Sickle Cell Disease · Priapism
Primary: Greater Than or Equal to a 50% Reduction in Priapic Episodes — 3; 3 Number of participants — p=1
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects
Phase 2 N=103 Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Effective Castration Rate Over 25 Weeks — 95; 89 percentage of participants
Phase 2 N=207 Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
Hepatitis B
Primary: Percentage of Participants With Local and Systemic Post-injection Reaction Rates — 38.2; 37.9; 37.2; 33.0 percentage of subjects
Phase 2 N=909 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
Asthma
Primary: Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period — 0.170…
Phase 2 N=11 Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
Progressive Supranuclear Palsy
Primary: Adverse Events — 23 Number of Adverse Events
Phase 2 N=72 Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
Asthma
Primary: Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12) — 52.13; 203.84; 248.98; 279.69 mL…
Phase 2 N=20 Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Alcoholism · Schizophrenia
Primary: Self Reported Weekly Alcohol Consumption — 23.4; 19.6; 15.7; 10.0 percentage of days
Phase 2 N=121 Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Multiple Myeloma
Primary: Overall Response Rate — 6; 1; 20; 43 Participants
Phase 2 N=889 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
Asthma
Primary: Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period — 0.059…
Phase 2 N=107 Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)
Skin Rash · Lung Cancer
Primary: Frequency of Participants Who Experienced Any Grade of Rash As Characterized By The Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0 — 44.5; 75.5 Percentage of…
Phase 2 N=7 Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Diabetes Mellitus, Type 1
Primary: Insulin Independence. — 2 Participants
Phase 2 N=27 Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC)
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 2; 1 participant